Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition

Strategies to enhance response to poly(adenosine diphosphate–ribose) polymerase inhibitor (PARPi) in primary and acquired homologous recombination (HR)–proficient tumors would be a major advance in cancer care. We used a drug synergy screen that combined a PARPi, olaparib, with 20 well-characterized...

Full description

Saved in:
Bibliographic Details
Published in:Sci Transl Med
Main Authors: Yang, Lu, Zhang, Youyou, Shan, Weiwei, Hu, Zhongyi, Yuan, Jiao, Pi, Jingjiang, Wang, Yueying, Fan, Lingling, Tang, Zhaoqing, Li, Chunsheng, Hu, Xiaowen, Tanyi, Janos L., Fan, Yi, Huang, Qihong, Montone, Kathleen, Dang, Chi V., Zhang, Lin
Format: Artigo
Language:Inglês
Published: 2017
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5705017/
https://ncbi.nlm.nih.gov/pubmed/28747513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aal1645
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items